the postoperative setting for patients with breast cancer. 1, 2 Recently, there has been an increased focus on using enhanced recovery pathways in reconstructive breast surgery to further improve outcomes, such as early mobilization, optimization of pain control, and earlier hospital discharge. [3] [4] [5] These enhanced recovery pathways aim to achieve early postoperative recovery by maintaining preoperative organ function and reducing surgical stress during and after surgery. The main principles of enhanced recovery pathways include preoperative optimization of the surgical patient, preoperative nutrition, avoidance of prolonged fasting, goal-directed fluid management, standardized multimodal analgesic and anesthetic regimens, early resumption of diet, and early mobilization in the postoperative period. [6] [7] [8] [9] Compared with conventional care models, enhanced recovery pathways have been shown to reduce morbidity and decrease hospital length of stay. [10] [11] [12] [13] Despite the increasing amount of evidence showing the benefits of enhanced recovery pathways for many surgical populations, [14] [15] [16] [17] [18] [19] the adoption of this strategy for patients undergoing microsurgical breast reconstruction has been slow. Only a few reports of enhanced recovery pathways being used in microsurgical breast reconstruction are available. [3] [4] [5] 8 These studies have typically focused on a homogeneous patient population or were limited to one or two microsurgeons. The purpose of this study was to assess how the introduction of a simple enhanced recovery pathway for microsurgical breast reconstruction among a larger group of surgeons with a heterogenous patient population affects outcomes such as opioid consumption and hospital length of stay.
PATIENTS AND METHODS

Study Design
This study was approved by the Memorial Sloan Kettering Cancer Center Intuitional Review Board (reference number 16-289) before commencing. Because this was a deidentified database review, the institutional review board waived the requirement for informed consent. We retrospectively studied perioperative data from patients undergoing microsurgical breast reconstruction using the enhanced recovery pathway at our institution between April and August of 2015. This group of patients was compared with a historical control group of consecutive patients who underwent immediate or delayed breast reconstruction with traditional postoperative care between June and December of 2013 (pre-enhanced recovery pathway). The historical control group was mostly treated using an opioidbased regimen with patient-controlled analgesia. Patients undergoing immediate or delayed breast reconstruction with a DIEP or muscle-sparing free TRAM flap were included in the study. For immediate reconstruction, patients undergoing either prophylactic or therapeutic mastectomies were included. All procedures were performed among seven plastic surgeons at a single cancer center. Patients who underwent a simultaneous procedure, such as oophorectomy, were excluded. All data were retrieved retrospectively from the patients' electronic medical records. The primary endpoint was length of stay, defined as the number of days from initial admission to hospital discharge. Secondary endpoints were opioid consumption, pain (assessed by the Likert pain scale), and incidence of complications within 30 days of surgery.
Enhanced Recovery Pathway
The enhanced recovery pathway was implemented as a collaborative effort among the anesthesia, nursing, and plastic surgery teams. The main elements of this enhanced recovery pathway included the following components. Preoperatively, patients received education to optimize surgery, including avoiding prolonged fasting (oral clear liquids until 2 hours before hospital arrival time). Intraoperatively, opioid use was supplemented with nonopioid analgesia (intravenous acetaminophen and/or ketorolac), and transversus abdominis plane blocks with liposomal bupivacaine were administered by the surgeon. In addition, antiemetic drugs (ondansetron or dexamethasone) were administered, and intraoperative goal-directed fluid management was guided by hemodynamic parameters, including the pulse pressure variation method. Postoperatively, intravenous ketorolac (15 mg) was administered every 6 hours for the first 3 days and then was transitioned to an oral equivalent for an additional 2 days. Breakthrough pain was covered with oral or intravenous opioids. Patient-controlled analgesia was eliminated in most patients. All patients were instructed to ambulate and start a regular diet on the first postoperative day, with the expectation of hospital discharge on postoperative day 3. Details of this protocol are illustrated in Figure 1 .
Surgical Technique
All patients underwent either DIEP or musclesparing free TRAM flap surgery, on the basis of intraoperative findings. The recipient vessels were the internal mammary artery and vein, with a portion of the third rib cartilage removed. Once recipient-and donor-site dissections were complete, 15 mg of intravenous ketorolac was given before anastomosis so that any potential bleeding would be controlled in the widely exposed operative field. In all patients who underwent muscle-sparing free TRAM flap surgery, wide-pore Prolene (Ethicon, Inc., Somerville, N.J.) mesh was used to reinforce the abdominal wall. Transversus abdominis plane blocks were administered bilaterally using liposomal bupivacaine: 20 ml of 1.3% (266 mg) liposomal bupivacaine was diluted with 180 ml of normal saline. Previously, an open technique was used involving direct dissection to the transversus abdominis fascia. We then used a sharp infiltration needle into the transversus abdominis plane under ultrasound guidance. Currently, a blind technique is used based on landmarks and tactile feedback, which can be administered more rapidly. An 18-gauge Tuohy needle is used to pierce the external and internal oblique fascia until resistance from the transversus abdominis fascia is met at the level of the anterior axillary line, approximately 2 cm below the costal margin. The Tuohy needle is curved and blunt, making it a safer choice for the blind technique, as the surgeon can feel the transversus abdominis fascia without easily penetrating it. Next, 40 ml of solution is introduced into the plane, after aspiration to ensure there is no intravascular injection. The remaining 120 ml of solution is used for supplemental injection around the fascial closure (within the rectus sheath itself) and along the inferior abdominal skin edge and drain sites. If a midline plication is performed superior to the umbilicus, direct injection into this area is important, as the transversus abdominis plane block will not cover the subxiphoid region. Closed suction drains were used followed by a standard layered skin closure. In this series, the mastectomy site was not injected. Flap monitoring was performed predominantly using a handheld Doppler device and, in some cases, a T.Ox system device (ViOptix, Fremont, Calif.).
Statistical Analysis
Fisher's exact test was used to evaluate continuous variables in the enhanced recovery pathway group compared with the pre-enhanced recovery pathway group. The Wilcoxon rank sum test was used to evaluate categorical variables. The two outcomes of interest were (1) hospital length of stay and (2) total postoperative opioid consumption (in morphine equivalents). The correlation between length of stay and total opioid consumption was evaluated using the Spearman correlation test. Exploratory examination indicated that the distribution of both outcomes were right-skewed. Therefore, the regression analyses of outcomes used the log-transformed versions of length of hospital stay and postoperative opioid consumption. Univariable linear regression analyses were performed to examine the relationship between each outcome of interest and enhanced recovery pathway status. Multivariable regression models were constructed, starting with all variables with p < 0.10 in univariable analyses. The secondary outcome of 30-day complications was compared between enhanced recovery pathway status using Fisher's exact test. All statistical tests were twotailed, and p < 0.05 was considered to indicate statistical significance. All analyses were performed using Stata 13 (StataCorp, College Station, Texas).
RESULTS
In total, 91 patients were included in this study. Forty-two consecutive patients underwent DIEP or muscle-sparing free TRAM flap breast reconstruction with the enhanced recovery pathway between April and August of 2015. The historical cohort (pre-enhanced recovery pathway group) consisted of 49 consecutive patients who underwent DIEP or muscle-sparing free TRAM flap reconstruction between June and December of 2013. As shown in Table 1 , patient demographics and preoperative characteristics were similar in both cohorts. There was no significant difference between the enhanced recovery pathway and preenhanced recovery pathway groups in the number of delayed and immediate reconstructions, type of procedure (DIEP or muscle-sparing TRAM flap), or laterality of reconstruction (Table 2) .
Intraoperative data are shown in Table 3 . Length of surgery was shorter in the enhanced recovery pathway group than in the pre-enhanced recovery pathway group: median, 7.2 hours versus 8.8 hours (p = 0.007) for unilateral procedures, and 9.1 hours versus 10.6 hours (p = 0.014) for bilateral procedures. Liposomal bupivacaine was not used in any of the patients in the pre-enhanced recovery pathway group and was administered to all patients in the enhanced recovery pathway group. The enhanced recovery pathway group received a significantly lower amount of intravenous fluid than the pre-enhanced recovery pathway group (3.85 liters versus 5.55 liters; p < 0.0001).
Postoperative data are listed in Table 4 . Hospital length of stay was 1 day shorter in the enhanced recovery pathway group than in the pre-enhanced recovery pathway group (4.0 days versus 5.0 days; p < 0.0001). Almost all patients (98 percent) in the pre-enhanced recovery pathway group used patient-controlled analgesia, compared with only 21 percent in the enhanced recovery pathway group (p < 0.0001). Among patients who required patient-controlled analgesia, the median duration of patient-controlled analgesia use was shorter in the enhanced recovery pathway group than in the pre-enhanced recovery pathway group (24.9 hours versus 41.0 hours; p = 0.011). The proportion of patients using ketorolac postoperatively was lower in the pre-enhanced recovery pathway group than in the enhanced recovery pathway group (8 percent versus 71 percent; p < 0.0001). Total postoperative intravenous morphine use was significantly lower in the enhanced recovery pathway group (46.0 mg versus 70.5 mg; p = 0.003). Patients in the pre-enhanced recovery pathway group had lower pain scores 18 to 24 hours after surgery and 24 to 48 hours after surgery: 6.0 versus 4.0 (p = 0.02) and 6.0 versus 5.0 (p = 0.02), respectively. Pain scores for the remainder of hospital length of stay were not significantly different between the two groups. As shown in Table 5 , there were no significant differences in the proportions of patients with complications (p = 0.2), readmissions (p = 1.00), or reoperations (p = 0.44) between the groups. There was a moderate correlation between the two outcomes of interest, length of stay and postoperative opioid consumption (Spearman correlation rho = 0.343; p = 0.0009).
Results of univariable linear regression analyses of both length of stay and opioid consumption are listed in Table 6 . All elements of the enhanced recovery pathway that were introduced (i.e., liposomal bupivacaine, postoperative ketorolac, goal-directed fluid management, and a shorter length of surgery) were significantly associated with reduced length of stay and less postoperative opioid consumption. Older age was an additional factor that predicted somewhat less postoperative opioid consumption (p = 0.001).
Multivariable models of both outcomes are presented in Table 7 . With respect to length of stay, after adjusting for intraoperative intravenous morphine 
DISCUSSION
Enhanced recovery pathways have been integrated into the treatment of patients undergoing colorectal surgery, among numerous other surgical populations, [14] [15] [16] [17] [18] [19] [20] with the ultimate goal of enhancing patient recovery. These multidisciplinary surgical care pathways have been shown to improve recovery, reduce length of stay, and optimize health outcomes and resource use. 8 We believe that enhanced recovery pathways that use a multidisciplinary approach and multimodal pain management to care for patients represent the future of plastic surgery.
However, to date, only a few enhanced recovery pathways have been described in the plastic surgery literature.
3-5,21,22 Batdorf et al. initially described a comprehensive enhanced recovery pathway for microsurgical breast reconstruction. 3 Although the enhanced recovery pathway group in their study had a lower body mass index and underwent more DIEP flap procedures, the findings were very compelling and made an important contribution to the use of enhanced recovery pathways for this patient population. Davidge et al. 21 examined patients undergoing TRAM flap breast reconstruction. They identified the use of multimodal analgesia, lower American Society of Anesthesiologists class, and surgery more than 6 months after implementation of the pathway as predictors of shorter time to discharge. Bonde et al. 5 reported outcomes among patients undergoing unilateral breast reconstruction and found a decrease in mean length of stay, from 7.4 days to 6.2 days. They continued to improve on their fast-track protocol with the identification of specific factors that prolonged hospital stay. A more recent article by the same group 22 demonstrated a dramatic reduction in mean length of stay, to 3.1 days, among 16 consecutive patients. These patients mostly underwent delayed, unilateral DIEP flap procedures; their outcomes continued to improve as the enhanced recovery pathway implementation efforts continued.
Whereas promising results have been reported with the use of enhanced recovery pathways for breast reconstruction, the particular practice environment may also influence outcomes. Previous studies have introduced enhanced recovery pathways into practices composed of one or two microsurgeons. Introducing enhanced recovery pathways into practices comprising a larger, heterogenous group of surgeons performing a variety of surgical techniques may result in a wider range of outcomes. The aim of this study was to determine whether the implementation of a basic enhanced recovery pathway into such an environment would reduce hospital length of stay and overall opioid consumption. The core elements of this enhanced recovery pathway include multimodal analgesia, goal-directed fluid management, an emphasis on early ambulation, and a regular diet the morning after surgery (Fig. 1) . In this study, we found that the enhanced recovery pathway was effective even when implemented among several surgeons with different practice patterns.
The current enhanced recovery pathway at our institution is based on combined ketorolac and liposomal bupivacaine transversus abdominis plane block administration without patient-controlled analgesia. This is a fundamental departure from the traditional opioid-centered model, where patients often receive patient-controlled analgesia for 2 or 3 days. Opioids are very effective at treating pain and remain an important component of postoperative pain relief, but sole reliance on narcotics is associated with opioidrelated adverse drug events. These include nausea, constipation, and obtundation, which can lead to serious consequences in high-risk patients. In this study, patients in the pre-enhanced recovery pathway group, who received a patient-controlled analgesia-centered regimen, had higher total morphine equivalents and longer length of stay, which significantly contribute to higher health care costs. [23] [24] [25] In addition, patients using patient-controlled analgesia are often reluctant to give it up, and the extra line and intravenous pole may interfere with early postoperative ambulation and recovery. Similar to Batdorf et al., we noted a decrease in patient-controlled analgesia use in the enhanced recovery pathway group, from 98 percent to 21 percent. This reduction was made possible by the administration of liposomal bupivacaine transversus abdominis plane blocks and ketorolac. Although concerns about bleeding with ketorolac use exist, there were no differences in complications between the enhanced recovery pathway and pre-enhanced recovery pathway groups, similar to the findings of other studies. 26, 27 However, these data are confounded by selection bias, as patients who bled more easily during surgery were generally not given ketorolac.
One question we asked was: Did the addition of ketorolac to the liposomal bupivacaine reduce opioid consumption or length of stay? All of the patients in the enhanced recovery pathway group received liposomal bupivacaine transversus abdominis plane blocks, and 71 percent received scheduled postoperative ketorolac. Only 8 percent of patients in the pre-enhanced recovery pathway group (n = 4) received postoperative ketorolac. In this study, liposomal bupivacaine was the only variable that was significantly correlated with a reduction in both hospital length of stay and total postoperative opioid consumption. The addition of ketorolac did not further decrease length of stay, but it did significantly reduce opioid consumption, compared with liposomal bupivacaine alone (p = 0.016).
By the use of goal-directed fluid management, we also noted a significant decrease in intraoperative fluid administration in the enhanced recovery pathway group. Clinical outcomes can be adversely affected by inadequate or excessive fluid administration. Euvolemia is important in microsurgery, as previous studies have reported increased flap complications with excessive fluid administration. 28, 29 Enhanced recovery pathway implementation significantly reduced hospital length of stay, from 5.0 days to 4.0 days, with no increase in postoperative complications. In addition, this pathway also significantly decreased total postoperative opioid consumption by 35 percent, with significant reductions seen on postoperative days 1 and 2. Interestingly, although patients in the enhanced recovery pathway group had lower opioid consumption, they reported higher amounts of pain 18 to 48 hours after surgery, compared with the pre-enhanced recovery pathway group. Patients in the enhanced recovery pathway group were out of bed and walking earlier than patients in the pre-enhanced recovery pathway group, which may have affected pain scores. In addition, pain scores are inherently subjective, interpreted differently among individuals, and are dependent on the activity of the patient at the time of the assessment. 30, 31 Opioid consumption is a more objective endpoint and reflects the patient's need for pain control. Replacing patient-controlled 
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analgesia with liposomal bupivacaine and ketorolac in the enhanced recovery pathway may mitigate the adverse drug events seen with high levels of opioid consumption and lead to a reduction in length of hospitalization.
There are several confounding factors that should be mentioned. The operative time in the enhanced recovery pathway group was 1 hour shorter than that in the pre-enhanced recovery pathway group. This finding is likely a result of the recent trend at our institution to perform microsurgical cases with two microsurgeons, to reduce the patient's time under general anesthesia. In addition, a patient's preoperative expectations regarding hospital length of stay may influence this variable, although this was not formally evaluated in the study. Finally, this study was retrospective in nature and limited by the sample size.
CONCLUSIONS
In summary, implementing an enhanced recovery pathway in microsurgical breast reconstruction is a fundamental step toward making autologous reconstruction a more palatable option for patients, with several significant benefits. As microsurgical success rates and cosmetic outcomes have improved and surgical times have become shorter, the final hurdle in breast reconstructive surgery has been the perioperative patient experience. The results in this study demonstrate that an enhanced recovery pathway can improve the perioperative patient experience by reducing hospital length of stay and total opioid consumption. In addition, this study was a collaboration among the anesthesia, nursing, and plastic surgery teams and reflects the increasing trend of multidisciplinary integration in plastic surgery care pathways to minimize the burden of recovery for our patients. Although these results are promising, more studies are needed to determine the most effective elements in an enhanced recovery pathway. 
